SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LemonHead who wrote (530)4/1/1998 11:16:00 PM
From: Rick Strange  Read Replies (1) of 1491
 
Keith, I don't know if can buy your concept that upgrading BOL is a backdoor attempt to push PARS (maybe that wasn't what you were saying). But I do think that PARS was a very big factor in that upgrade. Look at BOL:
1997 1996
Revenue $1.916 billion $1.927 billion
Net Income $49.40 million $83.10 million
Earnings Per Share $0.89 $1.47

The only thing new that I see new here is "Men In Black" hyped RayBan sales and PARS. It is essential for BOL to develop higher margin lines of business if it is to reverse this profit squeeze and Rx drugs offers one avenue. Lotemax and Alrex are BOL first Rx drugs that aren't generics. They are aware that the whole industry is looking over their shoulder during the roll-out and PARS should benefit from that extra effort by BOL to show potential future partners what they can do.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News